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Nos ultimos anos, vêm se acumulando as evidências sobre a necessidade de vanádio dos
organismos mais evoluídos. Estudos de compostos modelos constituem-se numa importante
ferramenta para o entendimento dos diferentes aspectos da bioquímica deste bioelemento. Neste
artigo, apresentamos os resultados dos nossos estudos, assim como os de outros grupos de pesquisa,
sobre compostos modelos relacionados a vários aspectos do metabolismo e detoxificação do vanádio
e a haloperoxidasas dependentes do vanádio. São também apresentadas informações sobre as
interações do cátion oxovanádio(IV), relevante do ponto de vista biológico, com bioligantes
importantes, tais como nucleotideos, carboidratos, fosfatos e outros sistemas correlatos.
Increasing evidence on the need of the higher forms of life for vanadium has accumulated during
recent years. Model studies have become a very important tool to attain a better understanding of
different aspects of the biochemistry of this bioelement. In this account we present the results of our
own studies, as well as those of other research groups, on models related to different aspects of its
metabolism and detoxification and to vanadium dependent haloperoxidases. Additional information
about the interaction of the biologically relevant oxovanadium(IV) cation with important bioligands,
such as nucleotides, carbohydrates, phosphates and related systems are also presented.
Keywords: vanadium, model studies, metabolism, detoxification, haloperoxidases, biologically
relevant ligands
1. Introduction
The biological effects, biodistribution and toxicology
of vanadium, such as its requirement and pharmacological
activity, are areas of increasing research interest. Although
numerous biochemical and physiological functions have
been suggested for this element, and despite the amount
of the knowledge so far accumulated, vanadium still does
not have a clearly defined role in the higher forms of life.1-5
The best evidence for a biological role of vanadium
comes from bacteria (the so-called alternative nitrogenases
in which vanadium replaces molybdenum in the FeMo-
cofactor of some Azotobacter species)4-7 and from plants
(vanadium- dependent haloperoxidases found in some
algae, lichens and fungi).4,5,8,9
On the other hand, experiments with laboratory animals
have shown that vanadium deprivation enhances abortion
rates, reduces milk levels during lactation and produces
thyroidal disorders. Other evidence points to the possible
role of vanadium in the regulation of ATP-ases, phosphoryl
transfer enzymes, adenylate cyclase, and protein kinases.
However, many actions of vanadium can be also explained
by its having a role similar to, or enhancing recently
described growth factors such as the epidermal growth
factor, the fibroblast growth factor and even insuline.10
Like molybdenum, vanadium occupies an exceptional
position among the bioelements because both, anionic and
cationic forms can participate in biological processes.3,5,11,12
In its anionic forms (vanadates(V)), it resembles phosphates,
but in its cationic forms - mainly as VO2+ - it behaves like a
typical transition metal ion, which competes with other metal
cations in coordination with biogenic ligands or compounds.
This duality, together with the facility with which it changes
oxidation states and coordination environments, may be
responsible for the very peculiar and somewhat unparalleled
behavior of this biometal.5,12
Aspects of the coordination chemistry of vanadium
relevant to its presence and activity in biological systems
have been recently reviewed.2-4,11-14 In this account we will
present some of our recent results of studies on model
systems related to aspects of the biochemistry of vanadium
and those of other research groups working in this field.
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2. Model Studies Related to Vanadium
Metabolism
Although information about the metabolism of
physiological amounts of vanadium in the higher forms of
life remains scarce, an increasing amount of data has
accumulated during recent years, mainly from animal
studies. Some general aspects related to the absorption,
transport, biological transformations, toxicity and
excretion of vanadium become understandable.15,16
In Figure 1 we present a summary of this knowledge,
briefly summarized, as follows: Dietary vanadium occurs
mainly as H2VO4- and enters cells probably through the
phosphate transport mechanism. Most of the ingested
vanadium(V) undergoes a rapid one-electron reduction in
the gastrointestinal tract, consistent with the fact that
vanadium (V) is a rather strong oxidizing agent, especially
at low pH. Most of the ingested and reduced vanadium
remains unabsorbed and is excreted. Strong association
between VO2+ and dietary fiber is postulated. In vivo, all
the vanadium is converted to a common form. The organ
distribution is essentially independent of the oxidation
state and chemical nature of the form of the element.
Evidently VO2+ undergoes autooxidation to vanadate in
the presence of oxygen, whereas glutathione, ascorbate,
cysteine and similar reducing agents can reduce vanadate.
This means that endogenous reducing agents and dissolved
oxygen ensure that both vanadium(V) and vanadium(IV)
species are present in serum. Experimental evidence points
to a relation between vanadium and iron metabolism. It
has been suggested that the iron- transport protein
transferrin may be also involved in vanadium transport. It
remains to be determined if ferritin, the storage protein for
iron, is also a useful storage system for vanadium.
Interactions between vanadium species and serum albumin
are probable, but very little is known about these processes
and the possible nature of the complexes generated. Bone
seems to be the major sink for vanadium. Final excretion
of the small fraction of ingested and not retained vanadium
occurs mainly through urine, as low-molecular-weight VO2+
complexes. Biliar excretion seems to be a secondary route.
We have performed a series of model studies related to
different steps of the metabolic patterns in order to clarify
some essential aspects.
2.1. Complexes of glutathione and related ligands
Reduced glutathione (GSH, Figure 2a), the tripeptide
γ-L-glutamyl-L-cysteinylglycine, the major non-protein
thiol present in animal cells, is an extremely important
biological reducing agent, involved in detoxification
processes of exogenous materials17 and apparently plays a
central role in vanadium metabolism.
Besides its reducing potential GSH can act as a ligand
for the stabilization of the VO2+ oxocation.12,18,19 Conse-
quently, we have repeatedly investigated the VO2+/GSH
system. Our first studies, using electronic absorption
spectroscopy, have shown that the interaction is strongly
dependent on the initial metal-to-ligand ratios and the pH
of the solution, and at least two different species were
identified.20 More detailed speciation studies of this system
have shown an even higher complexity.21,22 In the most
recent and complete study, combining pH-potentiometry
with EPR spectroscopy, visible absorption and circular
dichroism measurements, it was shown that in the pH range
between 5 and 7.5 and at any ligand-to-metal ratio between
Figure 1. Schematic representation of vanadium metabolism in higher forms of life.
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10 and 140, the predominant complex, is a 2:1 species in
which each GSH molecule coordinates through one O-
atom of the deprotonated carboxylate group and the amino
N-atom of the glutamyl residue.22 Four other species were
identified in other pH-ranges.22 Previous EPR studies of
this system also support VO2+ interaction through oxygens
of the deprotonated carboxylate groups, and NH2
moieties.23
On the other hand, a series of model compounds with
sulfhydryl-containing pseudopeptides, and investigated
by a combination of numerous physicochemical
techniques, also demonstrates the predominance of the
cited 2:1 species in the pH range 5-7.24
The oxidation product of glutathione (GSSG, Figure
2b) can also interact with the VO2+ cation, and model
speciation calculations reveal that in the pH range 6-7,
GSSG is a more efficient oxovanadium(IV) binder than
GSH.22 Two different 2:1 complexes, easily interconverted
simply by changing the metal-to-ligand concentrations,
are generated in the GSSG/VO2+ system. At low GSSG
concentrations, coordination takes place through
carboxylate groups, whereas at higher concentrations,
N-donors appear to be principally involved in coordi-
nation.25 EPR studies at a 25 : 1 ligand-to-metal ratio
suggest coordination through one or two monodentate
carboxylate groups or through one or two α-amino acid
moieties, i.e., COO– + NH2 or 2COO– + 2 NH2.23
Most recently, Costa Pessoa et al.26 performed a detailed
speciation study of this system. They concluded that in
the pH range 6-8 and at a ligand-to-metal ratio = 10, a 1:1
species predominates. Coordination in this complex
involves one carboxylate oxygen-atom and the NH2 group
of the two terminal glutamyl moieties of GSSG.
These results confirm that both GSH and GSSG may
participate in the stabilization and in the transport of VO2+
immediately after the GSH-mediated reduction of
vanadate(V) in cellular systems.16,22
The amino acid L-cysteine is another potential
reducing agent for vanadate in biological systems. Model
studies in the VO3–/cysteine system show that vanadate is
rapidly reduced, irrespective of the pH of the solution. At
pH 6.8, reduction is followed by the formation of a purple
complex. In this 2:1 ligand-to-metal species, the VO2+
cation interacts with the amino N-atom and the
deprotonated –SH group of two amino acid molecules.27
This complex seems to be similar to the VO2+ complexes of
cysteine esters of the same stoichiometry, which were
isolated in the solid state.28,29 We also demonstrated that
oxovanadium(IV) interacts with cystine, the oxidation
product of L-cysteine. In this case, coordination apparently
occurs through the carboxylate and amino groups.30 These
results suggest that again both the excess of amino acid or
its oxidation product was bind to the VO2+ cation.
2.2. Oxovanadium(IV) complexes of L-ascorbic acid and
of its oxidation products
L-ascorbic acid (vitamin C, Figure 3) is another
possible natural reducing agent of vanadates(V) to
oxovanadium(IV). The reduced species can interact with
the acid and with some of its oxidation products.12,31,32
A detailed study of the interaction of L-ascorbic acid
with the VO2+ cation showed that different complexes are
generated in solution at different pH-values. Some of them
were isolated as powdered solids. As shown by
spectroscopic studies, in these complexes the acid acts as
a monodentate ligand through its deprotonated 3-hydroxo
group, generating species of very low stability, consistent
with the absence of chelation, suggesting that these VO2+/
ascorbate complexes are probably not significant in the
stabilization of the reduced vanadium.
On the other hand, the VO2+ cation might interact with
some of the species generated after the oxidation of
L-ascorbic acid.32 Dehydroascorbic acid, which is the
primary oxidation product, is very unstable and undergoes
a rapid series of transformations, first generating 2,3-
diketogulonic acid, which can be further degraded to a
mixture of oxalic and L-threonic acids.12,16,32
Dehydroascorbic acid interacts rapidly with VO2+.
Solutions of these adduct are highly unstable towards the
oxidation of the ligand. The VO2+/dehydroascorbate
complex hydrolyzes irreversibly with opening of the
lactone ring, generating a 2:1 ligand-to-metal complex, in
which the enolized form of 2,3-diketogulonic acid is
bidentate. A sodium salt of this complex anion, of
composition Na2[VO(C6H6O7)2].3H2O, has been isolated
and characterized.32
Figure 2. Reduced glutathione (a) and oxidized glutathione (b).
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Recently, we characterized some other VO2+ -complexes
of this type, obtained as microcrystalline powders, by direct
interaction of sodium metavanadate with ascorbic acid.33
2.3. Transferrin and serum albumin complexes
It is well known that in the oxidation states +3, +4 and
+5, vanadium binds tightly to transferrin 3,13,34, forming
vanadium-modified transferrins, which are believed to be
involved in vanadium transport in higher organisms.35
Nevertheless, the coordination environment around
vanadium in these systems is not yet totally known.
Vanadium(V) interaction with human serum transferrin
has been investigated in detail, showing that two
equivalents of vanadate are reversibly bound at the two
metal-binding sites of the protein.36 The interaction was
also modeled using the hexadentate ligand ethylenebis-
(o-hydroxyphenlylglycine) showing that, at pH 9.5, the
vanadium is bonded to phenolic residues as the VO2+
cation.36
In the case of the VO2+-complex of human lactoferrin,
an octahedral structure with O3N equatorial coordination,
involving one tyrosinate, one aspartate, one histidine and
one monodentate carbonate, with another tyrosinate trans
to the V=O bond has been proposed, on the basis of a
computer simulation, using the atomic coordinates of the
FeIII and CuII complexes.37 Vanadium(III), as V3+, and
vanadium(V) as VO2+, can also be accommodated in a
similar environment.37
Recently, Neves et al.38,39 have prepared some
interesting model systems for the VO2+-transferrin complex,
using N,O-donor ligands. With some of these models they
were able to reproduce UV-Vis and EPR properties of
oxovanadium(IV) complexes of human serum transferrin
and ovotransferrin and they advanced some new proposals
about the coordination sphere of vanadium in these
systems. It has also been shown that some of these
complexes can be oxidized chemically or electroche-
mically to the respective vanadium(V) complexes without
changing the coordination sphere of the vanadium.39
Some aspects of the vanadium/albumin interactions
are now understood.13,34 In one of the first EPR studies of
the VO2+/bovine serum albumin system, it was found that
the cation binds tightly probably at the specific sites for
CuII, located at the N terminus of the polypeptide chain.
There are also four or five additional weaker binding sites
for VO2+ at carboxylate groups of the protein. However, the
nature of the metal coordination sites could not be
unambiguously established.40
The interaction of VOSO4 and NaVO3 with human serum
albumin (HSA) was also investigated in aqueous solution
at physiological pH, using gel and capillary electrophoresis
and IR spectroscopic techniques. Gel electrophoresis
results showed that a maximum of twenty VO2+ cations is
bound per HSA molecule, at two sites with different
affinities. Capillary electrophoresis confirmed the
existence of two major binding sites for the
oxovanadium(IV) cation, whereas VO3- has only a very
weak binding affinity 41, consistent with previous studies.42
IR spectroscopic analysis showed that, as a conse-
quence of the VO2+/HAS interaction, major structural
changes are produced at the protein secondary structure.41
In a recent comparative study of the binding of
vanadate to HSA, human fresh frozen plasma and human
transferrin, it was demonstrated that the binding capacity
of HSA is about one thousandth of those of the other two
systems.43
2.4. Accumulation of vanadium in hard tissues and related
systems
Bone seems to be the most active vanadium
accumulator. The high skeletal retention of vanadate is
probably related to its rapid exchange with bone
phosphate, which must be favored by the strong similarities
of PO43- and VO43-.
In order to investigate this exchange, calcium
hydroxylapatite, Ca10(PO4)6(OH)2, was used as a model for
the inorganic phase of bone.44 Under physiological
conditions, the exchange was only observed with
amorphous material. These model studies showed that the
incorporation of small amount of vanadium into the
phosphate sites only produces weak distortions at
macroscopic (crystallographic parameters, crystal
ordering) and microscopic (local distortions, weakening
of chemical bonds) levels in the apatite lattice.44
Possible competition between VO2+ and CaII in the
hydroxylapatite lattice has also been analyzed.
Precipitation of Ca10(PO4)6(OH)2 in the presence of
oxovanadium(IV)45 as well as interaction of apatite
suspensions with the oxocation46 demonstrated that VO2+
is not incorporated into the apatite lattice, but that it is
strongly adsorbed on the material surface.46,47
In addition, in vivo experiments, analyzing bone
samples of rats treated with an interesting and promising
Figure 3. L-ascorbic acid.
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antidiabetic drug,48 bis(maltolato)oxovanadium (IV), by
means of electron spin-echo envelope modulation
(ESEEM) spectroscopy, suggest that phosphate is involved
in this surface interaction of VO2+ with bone.49
As it is known34,50 that VO2+ interacts with
tropocollagen,  it was useful to investigate whether it
interacts with components of the organic matrix of bone.
The interaction of VO2+ with chondroitin sulfate A (CSA),
a well-known muchopolysaccharide present in connective
tissues and other mineralized systems, was investigated in
aqueous solutions by electron absorption spectroscopy
and IR techniques. The generation of a complex species of
stoichiometry VO(CSA)2, involving metal coordination to
the carboxylate group and the glycosidic oxygen of the
D-glucuronate units of CSA was demonstrated.51 It was
also found that the two isolated components of CSA (D-
glucuronic acid and N-acetylgalactosamine) behave
towards VO2+ in a similar way as they do in the
muchopolysaccharide.52
2.5. Vanadium excretion
As mentioned in the introduction, ingested vanadium
is excreted most rapidly fecally. The postulated strong
association of VO2+ with dietary fiber must be facilitated
by the high affinity of the oxocation for a number of
functional residues such as carboxylate, phosphate or
hydroxo groups. However, very little information about
the characteristics of these interactions in the
gastrointestinal tract is available.
Concerning the final urinary excretion of the fraction
of vanadium initially retained there exist a number of
conflicting reports. Probably this excretion involves low-
molecular-weight VO2+ complexes.15 However, other
evidence also suggest the simultaneous presence of high
molecular-weight complexes.53
In recent studies the low-molecular-weight vanadium
species in urine was identified as a vanadium/ascorbate
complex.54,55 But on the basis of our studies with this system,
discussed above (section 2.2.), it is most likely that the
ligand may be any of the oxidation products of ascorbic
acid, perhaps 2,3-diketogulonic acid.
In the most recent study of this system it was shown
that, after intraperitoneally 48V injection, vanadium in urine
is found both as high-(protein-bound) and as low-
molecular-weight species. The partition of these forms
apparently depends on the time elapsed after vanadium
administration. Different high- and low-molecular-weight
forms were detected by chromatography depending of the
elapsed times. But, after 48 h vanadium is largely excreted
as a low-molecular-weight complex.56
3. Other Models of Biochemical Interest
A great number of other vanadium-containing
complexes and systems are also of direct biochemical
interest. In this section we restrict the information only to
some aspects of systems involving nucleotides, phosphates
and carbohydrates and some closely related ligands.
3.1. Interaction of VO2+ with nucleotides and related
materials
The coordination behavior of both vanadates(V) and
oxovanadium(IV) with nucleotides and their constituents
is of great interest in relation to competitive processes in
the regulation of the ATP-ases, ribonucleases and similar
systems, as well as with regard to the possible cancerostatic
action of vanadates.
As the field of VO2+/nucleotide interactions has been
recently reviewed,57 only the most important conclusions
are summarized here: in acid media all types of phosphate
nucleosides (mono-, di- and tri-phosphates) interact with
the cation, but only through the phosphate groups; at high
pH interaction takes place only through the deprotonated
OH-groups of D-ribose; at neutral pH di- and tri-phosphate
nucleosides generate VO(nucl)2 complexes at high ligand-
to-metal ratios; at lower ratios, participation of N atoms of
the nucleic acid bases occurs. The behavior of
monophosphate nucleosides is more complex. Important
ligand rearrangements take place with increasing pH.
Phosphate groups, together with OH-groups of D-ribose,
participate in coordination.
Interaction of the VO2+ cation with the nucleic bases58
and with nucleosides59 has also been investigated.
Even though different solid VO2+/nucleotide complexes
have been reported,60 but they have not been well
characterized. Our own experience in these systems has
shown that the isolation and purification of such complexes
is not easy.12
Simple and complex phosphates deserve special
attention, not only to the presence of vanadium in
nucleotides but also due to its participation in a wide range
of biological systems and processes.12
D-ribose-5-phosphate (Rib-5P) shows a similar solution
behavior to the monophosphate nucleosides61 and three
powdered solid oxovanadium(IV) complexes containing
this species were isolated and characterized.62 The
spectroscopic analysis of the light blue species [VO(Rib-
5P)(OH)(H2O)2].2H2O and [VO(Rib-5P)(H2O)3Cl shows
coordination through oxygen atoms of the phosphate
group which is bidentate in the first case and
monodentate in the second. In contrast, in the green
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Na6[VO(Rib-5P)2].6H2O complex, coordination takes place
through pairs of two adjacent deprotonated OH-groups of
the sugar moiety.
Phytic acid and thiamine diphosphates are other
biologically interesting phosphates. From the nutritional
point of view, phytic acid (mio-inositol hexaphosphate)
appears especially interesting because of its important
effects on the bioavailability of essential trace metals.63
Depending on the pH, the VO2+ cation interacts with
phytate forming both soluble and insoluble complexes.64
Regarding thiamine diphosphate (cocarboxylase,
TDP), a coenzyme that catalyzes the decarboxylation of
α-ketoacids, we have found that in the pH-range 3-4 a 1:1
complex with VO2+ is formed, and this involves only
O-phosphate bonds. The participation of the N(1) atom of
the pyrimidine ring in bonding has been suggested at
higher pH.65 A solid complex of composition
[VO(TDP)Cl].7H2O, was precipitated with ethanol from an
aqueous solution at pH 3.5. In this complex, the terminal
PO3 group of TDP is bidentate.66
Another complex, relevant to a better understanding
of the VO2+/phosphate interactions, is the recently
investigated trimer species Na6[(VO)3(P2O7)3].7H2O.67
3.2. VO2+ complexes of carbohydrates
As carbohydrates are the most abundant class of
compounds in the biosphere,12,68 the study of their
interaction with relevant vanadium species is of great
interest. It is well known that sugars interact with metal
ions either as reductants and/or chlelators.12,68 Most of them
reduce vanadates(V) to oxovanadium(IV) and complex this
cation. This field of vanadium biochemistry has also been
recently reviewed69 and therefore we shall reduce the
discussion only to its most relevant aspects.
Due to its strong hydrolytic tendency, the VO2+ cation
usually needs the presence of additional donor groups (e.g.
carboxylates) in the sugar molecule. Once bonded, it can
easily deprotonate the OH-groups and strongly coordinate
up to four of them. Oxovanadium(IV) complexes
coordinated by pairs of doubly deprotonated sugar
moieties usually display a very characteristic, three band,
electronic absorption spectrum.69,70
Oxovanadium(IV) coordination is favored in basic
media and only occurs with sugar molecules provided with
pairs of adjacent OH-groups.69,71
A great number of VO2+/monosaccharide complexes
have been reported in recent years. Their stoichiometries
are summarized in Table 1. All these complexes are green-
colored powders and are usually hygroscopic and very
soluble in water.
Only five oxovanadium complexes with disaccharides
as ligands have been so far reported. These are sucrose,74
turanose,74 maltose73,77 and lactose,78 with the following
stoichiometries:
Na3[VO(D-Suc)2OH].H2O
Na3[VO(D-Tur)2OH].3H2O
Na5[VO(D-Mal)2OH].10H2O
Na5[VO(D-Mal)2].CH3OH
Na4[VO(Lact)2].3H2O
Even though a number of oxovanadium(IV) complexes
with some carboxylate derivatives of carbohydrates and
sugar phosphates, and with polysaccharides, has been also
investigated, most of these compounds remains poorly
characterized.69
4. Model Studies Related to Vanadium
Detoxification
Contamination of the environment by vanadium has
Table 1. Composition of the known oxovanadium (IV) monosaccharide complexes
Complex Ref. Complex Ref.
[VO(D-Glc)2]  72 Na4[VO(L-Sor)2].3H2 O  76
Na2[VO(D-Glc)2].CH3OH  73 Na4[VO(D-Gal)2 ].5H2O  77
Na3[VO(D-Glc)2(OH)].5H2O  74 Na2[VO(D-Gal)2(OH)Cl].0.5H2O  75
Na2[VO(D-Glc)2(OH)Cl].H2O  75 Na2[VO(D-Gal)2].CH3OH  73
Na2[VO(D-Fru)2]  73 Na2[VO(D-Gal)2(H2O)]  76
Na6[(VO)2(D-Fru)5].4H2O  74 Na4[VO(D-Man)2 ].8H2 O  77
Na2[VO(D-Fru)2(OH)Cl].5H2O  75 Na3[VO(D-Man)2(OCH3)].4CH3OH  73
Na2[VO(D-Xyl)2].CH3OH  76 Na5[VO(D-Lyx)2(OH)].6H2O  77
Na4[VO(D-Xyl)2].5H2O  77 Na4[VO(D-Lyx)2].2H2O  76
Na2[VO(D-Xyl)2(HO)Cl].CH3OH.1.5H2O  75 Na2[VO(Ino)2]  76
Na4[VO(D-Ara)2].CH3OH.3H2O  76 Na4[VO(D-Rib)2].H2O  76
Na4[VO(D-Ara)2].5H2O  77 Na3[VO(D-Rib)2(OH)].4H2O  62
Na4[VO(L-Ara)2].5H2O  77 Na2[VO(D-Rib)2(OH)Cl].CH3OH  75
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dramatically increased in recent years, especially in the
most developed countries, due to the increasing use of
fossil fuels, which liberate V2O5 during combustion.79
Therefore, the toxicology and detoxification of vanadium
constitute an area of increasing development.
The degree of toxicity depends on the route of
administration, oxidation and chemical form and it is also
to some extent species-dependent. Vanadium compounds,
especially V2O5, are strong irritants of the airways and the
eyes. Acute and chronic exposure gives rise to conjunc-
tivitis, rhinitis, reversible irritation of the respiratory tract,
and to bronchitis, bronchospasms, and asthma-like diseases
in more severe cases. It has shown that it can produce
gastrointestinal distress, fatigue, cardiac palpitation, and
kidney damage. In humans, acute vanadium toxicity has
been observed in vanadium miners, as well as other
industrial workers exposed to high concentrations of the
element. The classic symptoms of this malady, referred to
as “green tongue” syndrome, are a green discoloration of
the tongue, accompanied by some of the cited disorders.80,81
It has been usually accepted that vanadium toxicity
increases with increasing oxidation state, vanadium(V)
being the most toxic.80,81
Living systems have developed defense mechanisms
to deal with the reactive and potentially harmful by-
products that arise from cellular metabolism and to control
the effects of exogenous substances that eventually invade
the organism (biological detoxification). Drugs have been
developed to chelate metal ions in vivo, not only to
eliminate excesses of essential metals but also to prevent
possible damage caused by nonessential, toxic elements
(chemical detoxification).
Some of the systems mentioned in this account are
evidently relevant to the toxicity and detoxification of
vanadium. Some of the metabolic processes (glutathione-,
ascorbate- or cysteine- mediated reduction of vanadates(V);
complexation of VO2+ by different biomolecules;
accumulation of vanadium in hard tissues) must play an
important role in biological vanadium detoxification.81
Most of the systems assayed for chemical detoxification
contain chelating or reducing/chelating agents.81 Animal
studies have demonstrated that the best detoxification
agent may be L-ascorbic acid.81-83 Its action is related to
the facility with which it reduces vanadium(V) to VO2+
and to the possibility that the oxocation generated may be
complexed by its oxidation products, as discussed above.
Better knowledge of the fundamental metabolic steps
and a thorough characterization of new vanadium species
with chelating or reducing agents may be useful for the
development of more potent and specific detoxification
agents for vanadium.
5. Model Studies Related to Haloperoxidases
Haloperoxidases are enzymes which catalyze the
oxidation of halides (Cl-, Br-, I-) by hydrogen peroxide,
resulting in the halogenation of appropriate organic
substrates.84 The presence of vanadium as an essential
component for a haloperoxidase was discovered in the red
algae Ascophyllum nodosum in 1984.85 Within these
vanadium-dependent haloperoxidases, both vanadium
bromoperoxidases, isolated mainly from algae, and
vanadium chloroperoxidases, found essentially in fungi,
have been subsequently identified.9
Recently, the crystal structure of a vanadium chloro-
peroxidase isolated from the fungus Curvularia inaequalis,
was reported by Messerschmidt and Wever.86 The structural
features of the active vanadium center seems to be
characteristic of all such systems.9 The metal, in the V
oxidation state, has a trigonal bipyramidal geometry,
ligated by azide (a result of the azide-containing
crystallization buffer), three non-protein oxygen atoms,
and a histidine N atom. In the native structure the azide
ligand, located in trans position to the histidine N atom, is
apparently replaced by an OH group.9, 86
The finding of a specific function of vanadium in
haloperoxidases allows new speculations, on its possible
functions in higher organisms. Thyroid peroxidase is one
of the best known animal haloperoxidases.84 As mentioned
previously, vanadium deprivation increases thyroid weight
and also affects the response of thyroid peroxidase
activity.5,10 Perhaps, vanadium plays some role in the
halogenating activity of this enzyme.
A great number of model studies have been performed
recently, in an attempt to understand better the structural
characteristics of the metal site as well as to elucidate the
reaction mechanisms the vanadium-dependent halo-
peroxidases.
All the information so far accumulated shows that
vanadium remains in the V oxidation state during the entire
catalytic cycle and it has also been demonstrated that
during the process one peroxide group is bonded to the
metal.4,87 A variety of mechanistic studies has been
performed using different vanadium/peroxide complexes
as model systems.4,88-91 Some vanadium-based semi-
synthetic and biomimetic models have also been assayed
as catalysts for enantioselective oxidations.92
Recently, we have also initiated some model studies
related to these natural systems, investigating the kinetics
of the bromination of phenol red by the peroxo-
vanadium(V) species generated by acid decomposition of
[VO(O2)2(NH3)]- and [O{VO(O2)2}2]4-.93
Numerous model studies related to the characteristics
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of both the active vanadium (V) site and the catalytically
inactive reduced oxovanadium(IV) site, have been also
performed.4,14,94-97
One interesting aspect of the structure of the active site
is the simultaneous presence of N- and O-donors and of
V=O and V-OH groups. The ligand 8-hydroxyquinoline,
the well-known analytical reagent oxine (HQ), is
particularly interesting for model studies related to these
systems and to other biologically relevant vanadium
centers. It normally stabilizes chelate complexes of the
types MQ2 and MQ3, generating MN2O2 or MN3O3 and, in
certain cases, also MN2O3(OH) environments.
In spite of the fact that the simplest oxovanadium(IV)
complex of oxine, VOQ2, has been widely investigated,
several contradictory reports, mainly derived from its easily
oxidability, are found in the literature. 12 In order to extend
these studies, we have synthesized and characterized a
series of VO2+ complexes with different derivatives of oxine.
Those derived from 5,7-dihalogenated oxine are stable in
air but show a very complex solution behavior that
includes oxidation phenomena, ligand loss and
interactions with solvents. 98 On the other hand, the
presence of halogen atoms on the oxine ring has a
negligible effect on the thermal stability of the complexes.99
A detailed study of the magnetic behavior of these
complexes shows that a ferromagnetic interaction between
the VO2+ groups becomes operative at temperatures below
40 K with an exchange integral J 2.73 cm-1. 100 These results
constitute the first direct evidence of the formation of
...V=O...V=O... ferromagnetic chains in these and in similar
oxovanadium(IV) complexes.12,100
Other related complexes that were also investigated in
detail are the bis-chelated VO2+ species derived from 8-
hydroxyquinoline-N-oxide.101 and from 7-iodo-8-
hydroxyquinoline-5-sulfonic acid (the analytical reagent
ferron).102
Some vanadium(V) species containing oxine or its
derivatives as ligands are much more interesting in relation
to the active site of haloperoxidases. The complex
hydroxobis(8-hydroxyquinolinato)oxovanadium(V)
(Figure 4a) can be considered as an “inorganic analog” of
a carboxylic acid.12,103 Accordingly, it is possible to prepare
salts (Figure 4b), esters (Figure 4c) and dimer anhydrides
(Figure 4d). We obtained a great number of complexes of
these types and characterized them thoroughly by different
physicochemical methods,98,101,102,104,105 including detailed
electrochemical studies.106,107
Another class of model system related to this biological
site, in its reduced (inactive) form are the recently reported
species cis-[VO(OH)(bipy)2]+ and cis-[VO(OH)(o-phen)2]+
which structural analysis, as the BF4- salts, showed the
presence of a severely distorted octahedral coordination
with the vanadium(IV) above the mean equatorial plane
defined by three bipy (o-phen) N-atoms and the OH-group.
The oxo group and the remaining N-atom of one of the
organic ligands occupy the apical positions.108
Also, Schiff-base complexes of vanadium(V) and of
oxovanadium(IV) have often been investigated as useful
models for this and other biological systems containing
the metal.109-115
Finally, it is worthy commenting that numerous model
compounds developed for a better understanding of the
activity and action of vanadium-dependent halopero-
xidases and other biological systems containing this
element are also reagents in modern organic synthesis.116
It is pertinent to emphasize that a number of model
compounds investigated in relation to Amavadine, the
natural vanadium complex present in the fungus Amanita
muscaria (cf.117,118 and references therein), also have very
interesting catalytic capabilities.119
6. Conclusions and Perspectives
We hope the above discussion has clearly shown the
importance of model studies for a deeper understanding of
some fundamental aspects related to the relatively complex
biochemistry of vanadium. These studies have revealed
valuable information concerning vanadium metabolism,
toxicity, detoxification and catalytic activity. They have
also extended the coordination chemistry of vanadium,
especially that of the vanadium(IV) and vanadium(V)
oxocations, as a direct consequence of the use of a variety
of new ligand types. Nevertheless, there are a number of
very important and interesting problems that remain open.
A better understanding of vanadium metabolism
requires new efforts to comprehend its transport in both
Figure 4. Different compounds in the vanadium (V)/oxine system.
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anionic and cationic forms, and for the initial reduction
processes of vanadium(V) to VO2+ in the gastrointestinal
tract. It would also be interesting to obtain crystalline VO2+
complexes with glutathione and related ligands and to
explore further the interaction of this oxocation with serum
albumin, transferrin and ferritin. A better chemical
characterization of excreted vanadium species also seems
very important.
More detailed speciation studies, including the
determination of stability constants, are necessary for a
wider characterization of the VO2+/nucleotide systems.
Other efforts should be directed to structural
information on oxovanadium(IV) saccharide complexes.
It has not yet been possible to obtain single crystals
adequate for crystallographic studies,69 therefore EXAFS
studies, like those recently performed on iron-saccharide
complexes,120 should be attempted. Studies on the
interaction of the VO2+ cation with polysaccharides should
also be expanded, as these systems are of particular
biological importance.
The possible use of phosphonates and related ligands,
as well as the combination of appropriate reducing/
chelating systems for use in vanadium detoxification merits
further exploration.
Most of the model systems so far investigated, are also
good candidates for theoretical studies, which may be very
useful for a better understanding of stability, electronic
structures, and reactivity. Some recent examples of this
type of work are the molecular modeling of vanadium
peroxides121 and studies of the electronic structures of
Amavadine models.122
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